Merck Undeterred By Upcoming Singulair Loss; Focuses On Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck reports second quarter earnings, looking past the patent expiration of Singulair to the drugs it icurrently is developing to replace the revenues it is expected to lose.
You may also be interested in...
How Low Does Merck Need To Go? FDA Safety Concerns May Cut Suvorexant’s Dosing
FDA will ask an advisory committee whether Merck’s insomnia drug should employ the tiered dosing schedule proposed for the elderly and non-responders, but the agency seems inclined towards a dose even lower that the ones that were used in Phase III.
Merck’s Suvorexant To Face FDA Panel Scrutiny On Next-Day Driving Effects
The Peripheral and Central Nervous System Drugs Advisory Committee’s May 22 review of the first-in-class insomnia drug will include data from two studies assessing the compound’s residual effects on next-day driving.
Merck Insomnia Drug Shows Improvements; Filing On Track
Merck is confident it can compete in the highly generic insomnia market; Phase III results show the insomnia drug suvorexant may have further benefits for patients.